Profile data is unavailable for this security.
About the company
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
- Revenue in USD (TTM)0.00
- Net income in USD-23.72m
- Incorporated2018
- Employees13.00
- LocationMaia Biotechnology Inc444 West Lake StreetSuite 1700, Suite 1700CHICAGO 60606United StatesUSA
- Phone+1 (312) 416-8592
- Fax+1 (302) 655-5049
- Websitehttps://maiabiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spero Therapeutics Inc | 110.98m | 23.40m | 79.76m | 46.00 | 3.51 | 0.8283 | 3.37 | 0.7187 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Serina Therapeutics Inc | 137.00k | -20.96m | 79.93m | 4.00 | -- | -- | -- | 583.44 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Assembly Biosciences Inc | 12.95m | -51.36m | 81.32m | 65.00 | -- | 2.48 | -- | 6.28 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 81.60m | 1.00 | -- | 0.4556 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Maia Biotechnology Inc | 0.00 | -23.72m | 83.20m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.09m | 91.00 | -- | 0.592 | -- | 2.70 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Chimerix Inc | 41.00k | -82.59m | 84.45m | 72.00 | -- | 0.4851 | -- | 2,059.74 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
SCYNEXIS Inc | 140.39m | 101.33m | 84.63m | 29.00 | 1.11 | 1.14 | -- | 0.6028 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
Cue Biopharma Inc | 7.02m | -49.97m | 84.64m | 53.00 | -- | 2.82 | -- | 12.06 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Anixa Biosciences Inc | 210.00k | -10.74m | 84.85m | 4.00 | -- | 3.43 | -- | 404.06 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Allovir Inc | 0.00 | -179.53m | 85.85m | 112.00 | -- | 0.712 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
IO Biotech Inc | 0.00 | -88.50m | 86.96m | 68.00 | -- | 0.7532 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 281.68k | 1.37% |
Centric Wealth Management LLCas of 31 Mar 2024 | 67.20k | 0.33% |
Geode Capital Management LLCas of 31 Mar 2024 | 53.26k | 0.26% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 45.70k | 0.22% |
Jane Street Capital LLCas of 31 Mar 2024 | 25.07k | 0.12% |
Citadel Securities LLCas of 31 Mar 2024 | 23.75k | 0.12% |
Naviter Wealth LLCas of 31 Mar 2024 | 22.17k | 0.11% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 21.30k | 0.10% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 20.27k | 0.10% |
Renaissance Technologies LLCas of 31 Mar 2024 | 19.00k | 0.09% |